AIRCHILL · Product concept
One device. Ventilation and controlled cooling.
AIRCHILL is being developed as a transport ventilator with controlled respiratory cooling, for structured emergency-care workflows. It is not an approved product and carries no clinical outcome claim.
Mechanism
Four controlled steps between the gas source and the patient.
The cooling capacity is not the interesting engineering problem. Control is: delivering a defined temperature without compromising ventilation, oxygenation, humidity or airway integrity.
Cold source
Oxygen-carrying gas stream or cryogenic source.
Thermal control
Controlled warming, mixing and humidification.
Ventilation
Defined temperature, flow, FiO₂ and pressure.
Heat extraction
Airway, lung and cerebral perfusion.
The demonstrator used in the preclinical experiments. Technology readiness is conservatively rated at TRL ≈ 4; the product architecture is not frozen.
Own photograph. TRL classified per the EU definition, Horizon Europe Annex G.
Infrared thermography at the start of cold air delivery and 23 minutes in. Surface temperature drops visibly; quantification gave roughly 0.3 °C per minute under endonasal delivery.
Final report, BMBF grant 031A530, University Medical Center Hamburg-Eppendorf, 2017.
MVP scope
A deliberately narrow first product.
The six-in-one platform remains the vision. The investable first step is smaller and can be approved.
The minimum viable product
Transport ventilation with controlled respiratory cooling · start together with established airway management · no cold volume bolus and no separate cooling catheter · interfaces to monitoring, documentation and telemedicine.
Platform extensions
Suction, ECG and defibrillation and telemedicine are added after the MVP through OEM modules or interfaces. They are not part of the current product claim.
Clinical workflow
Designed for gated adoption, not for a shortcut.
Any clinical workflow needs inclusion criteria, airway-management rules, monitoring, stop criteria and training. Those belong in protocol, usability and risk-management work before routine use.
Eligibility and setup
Protocol-defined selection, device checks, trained operators.
Ventilation and monitoring
Controlled intervention with respiratory, temperature and safety monitoring.
Handover and follow-up
Documented transition into the receiving hospital’s temperature-control pathway.
Differentiation
Where we stand against RhinoChill — and where we do not.
Integration, safety data, timing
Cooling that runs on the ventilation already in place rather than as a second device. Preclinical airway safety for the endotracheal route is documented over six hours at −20 °C. RhinoChill works with perfluorohexane; our route does not.
“Lower airway, therefore better”
Our own final report measured low, locally limited cooling performance for the endotracheal route because of dead-space ventilation, and recommended the endonasal route. Whoever switches or combines routes has to say so. The lower airway is a product objective, not a demonstrated advantage.
RhinoChill has carried a CE mark for commercial use, class IIb, since April 2011 (NICE MIB4). PRINCESS (Nordberg P et al., JAMA 2019;321:1677–1685, n = 677) missed its primary endpoint of good neurological outcome at 90 days. No CE-marked device was found that cools through the lower airway in combination with ventilation; the absence of a find is not proof, and EUDAMED and freedom-to-operate searches are outstanding.
Protection
Two granted patents, one open question about who holds them.
The core idea — a transportable device that lowers body temperature through the airway with a cooled, oxygen-carrying gas flow — is granted in Europe and in the United States, from a priority filed in September 2016. Both records are public and linked below.
Transportable device and system for lowering the body temperature of a mammal over the airways, in particular of a human, by means of a cooled, oxygen-containing gas flow
Transportable device, system and method for providing a cooled, oxygen-containing gas flow
The applicant on record is a natural person, the inventor, not Ethicalsaving gUG. We say that here rather than let a diligence process find it: assignment or an exclusive, worldwide, sublicensable licence to the operating company is a condition before any financing closes. Until that is executed, nothing in our material claims that the company owns these patents.
Checked against the public patent registers on 8 August 2026. Inventor Fabian Temme. The registers list a natural person as applicant, not the operating company — see the ownership note above. Records: EP3509683B1 · US11395900B2 · WO2018046128A1. Term runs to 9 September 2037 subject to fees and legal validity. Validation states, annuity payments, opposition status and the scope of the granted claims against the planned product have not been assessed.
Status
A development project — not an offer for clinical sale.
AIRCHILL is not presented here as CE-marked, FDA-cleared or available for routine patient treatment. Intended purpose, classification and claims remain subject to development, clinical evidence and regulatory review.
Ventilation, thermal systems, verification.
If you build emergency ventilators, thermal systems or airway consumables, we would like to talk.